Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2025-04-02 Capital/Financing Update
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the intimation of a Share Purchase cum Subscription Shareholders’ Agreement and Power Supply Agreement between Alivus Life Sciences Limited and Torrent Urja 19 Private Limited. It includes detailed disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs material events and disclosures by listed companies. The content focuses on the acquisition of a stake in a renewable energy company, including details such as percentage acquired, consideration, and background of the target entity. This is a regulatory announcement about a capital investment transaction and not a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive disclosure details. The document fits best under Capital/Financing Update (CAP) as it informs about a financing-related transaction and share subscription agreement.
2025-04-02 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is an official communication dated March 7, 2025, informing the stock exchanges about the allotment of equity shares under an Employee Stock Option Scheme. It details the number of shares allotted, the increase in paid-up capital, and compliance with SEBI regulations related to share-based employee benefits. The content focuses on the issuance of new shares and the resulting change in capital structure. There are no financial statements, earnings data, or management discussion. The document is a formal announcement of a share capital change due to employee stock option allotment, fitting the category of Share Issue/Capital Change.
2025-03-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges regarding upcoming meetings with investors and analysts. It references Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) – Regulations, 2015, which pertains to disclosure of material events or information. The content is about scheduling and informing about investor/analyst meetings, not the content of the meetings or any financial results. The document length is only 2050 characters, indicating it is a brief announcement rather than a detailed report or transcript. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Investor Presentation or Call Transcript since it does not contain presentation or transcript content itself.
2025-03-03 English
Demise
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the sad demise of an Independent Director of the company. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The content focuses on informing about a change in the board due to the death of a director, including cessation of committee memberships. There are no financial statements, earnings data, or report attachments. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-02-27 English
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. It reports receipt of an order from the Goods and Service Tax Department regarding a tax-related matter for FY 2020-21. The document includes details of the order, the authority, and the financial impact, but it does not contain any financial statements, management discussion, or detailed report content. The document length is 3237 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. It is a regulatory disclosure about a legal/tax proceeding but does not qualify as a full Legal Proceedings Report (LTR) because it is a regulatory mandated disclosure under SEBI LODR. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance disclosures that do not fit other categories.
2025-02-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) disclosing an upcoming investor/analyst meeting as per Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) – Regulations, 2015. It provides details of the meeting date, mode, place, and type. The document is short (1940 characters) and serves as an announcement of an investor/analyst meeting rather than a detailed report or presentation. It does not contain financial data, management discussion, or any report content. Therefore, it fits best under the category of Investor Presentation (IP) or a related category. However, since it is only an intimation of the meeting and not the presentation itself, and given the options, the closest and most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement about investor meetings under SEBI regulations.
2025-02-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.